



## **Open Monoclonal Technology grants unlimited OmniRat, OmniMouse and OmniFlic access to another global pharmaceutical company**

**Palo Alto, California, January 7, 2014**

Open Monoclonal Technology, Inc. (OMT) today announced granting unlimited OmniRat<sup>®</sup>, OmniMouse<sup>®</sup> and OmniFlic<sup>™</sup> access to a global leader in generics and novel pharmaceuticals.

Under the agreement, the pharmaceutical company will be able to generate human monoclonal and bispecific antibodies against any target for any indication globally. The company will pay an upfront and annual platform access fees as well as clinical milestones and royalties for each successful product.

Dr. Roland Buelow, founder and CEO of OMT, said “OMT has made its therapeutic human antibody platforms available to the industry’s leading pharmaceutical, biotech, health care and R&D service companies. This new partnership is with one of the world’s largest generics and ethical drug companies that will be able to leverage their geographical reach and commercial strength to take full advantage OMT’s human antibody platforms.”

### **About Open Monoclonal Technology**

Open Monoclonal Technology, Inc. (OMT) is a leader in genetic engineering of animals for discovery of human therapeutic antibodies, *naturally optimized human antibodies*<sup>®</sup>, and the only company in the world with three transgenic animal platforms.

**OmniRat**<sup>®</sup> is the industry’s first human monoclonal antibody technology based on rats. OMT, in collaboration with Pfizer, has shown that OmniRat has a complete immune system with a diverse antibody repertoire and generates antibodies with human idiotypes as well as a wild-type animals make rat antibodies (Journal of Immunology 2013 Feb 15;190(4):1481-90).

**OmniMouse**<sup>®</sup> is a transgenic mouse that complements OmniRat and expands epitope coverage. Both deliver human antibodies with high affinity, specificity, expression, solubility and stability.

**OmniFlic**<sup>™</sup> is the first engineered rat with a fixed light chain for discovery of bispecific, fully human antibodies.

OMT’s antibody platforms have broad freedom to operate and use technology protected by new patents and patent applications. They are available for licensing worldwide for all targets and indications. OMT has granted unlimited platform access to Genentech, Janssen, Merck KGaA, Pfizer, Roche and Symphogen and individual target rights to some smaller biotech companies. The Genentech partnership includes continued forward engineering that is made available to OMT’s partners. OMT’s platforms can also be accessed via China-based WuXi AppTec as part of their global biologics discovery and development services.

For more information, please visit [www.omtinc.net](http://www.omtinc.net) or contact Brian Lundstrom, Chief Business Officer, Open Monoclonal Technology, Inc., Phone: +1-775-420-7750, E-mail: [bl@omtinc.net](mailto:bl@omtinc.net).